An antibody that targets a protein specific to prostate cells can be used to image prostate cancer more clearly and indicate how well drugs are working.
The launch of a 20-ton instrument and a facility for producing radioactive imaging molecules will allow our doctors and scientists to monitor cancers in unparalleled detail.